Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (NIH) (grant (number T32 CA 009621))
  • NIH ((5R01CA168863))